Our Goal
During the pandemic, government funding was doled out to major pharmaceutical companies to ensure people had free access to COVID-19 vaccines and related therapeutics. But Johnson & Johnson (JNJ) has failed to disclose how it accounts for public funding in its current and future pricing strategies for its COVID-19 products.
This is why, Tulipshare, alongside Oxfam, has submitted a proposal to JNJ requesting a report explaining whether and how JNJ subsidiary Janssen’s receipt of government financial support for development and manufacture of vaccines and therapeutics for COVID-19 is being, or will be, taken into account when engaging in conduct that affects access to such products, such as setting prices.